Vera Therapeutics, Inc ( VERA ). saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.

Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p